Kraus, Glasgow, Duty To Warn and the Learned Intermediary Doctrine

Client Alerts-Psychedelics and Mental Health Therapeutics Client Alerts-Health Care and Life Sciences

September 10, 2024

FDA Denies Approval of New Drug Application for MDMA and Requests Additional Study

Articles

August 8, 2024

What’s Next for MDMA?

Client Alerts-Litigation

July 16, 2024

The End of Chevron Deference and a Monumental Shift in the Regulatory Power of Administrative Agencies

Articles

July 12, 2024

The FTC’s Non-Compete Ban: Anticipated Impacts on the Health Care Industry

Articles

July 8, 2024

AI Demystified: The Transformative Impact of AI in Health Care

Client Alerts-Health Care and Life Sciences

June 10, 2024

FDA Will Not Object to Qualified Health Claims for Yogurt for Type 2 Diabetes Risk Reduction

Articles

April 12, 2024

Next-Gen Medical Devices: Evolving with AI to Ensure Safety and Efficacy

Articles

March 25, 2024

Second Circuit Baby Food Ruling Disregards FDA’s Expertise

Client Alerts-Psychedelics and Mental Health Therapeutics

March 21, 2024

FDA Breakthrough Therapy Designation for LSD Formulation

Articles

January 19, 2024

The Direct Primary Care Model: Considerations for NY Providers, Patients and Employers

Client Alerts-Psychedelics and Mental Health Therapeutics

January 3, 2024

Progress for Research Funding on Psychedelics for Military Personnel and Veterans/First Responders

Client Alerts-Psychedelics and Mental Health Therapeutics

December 21, 2023

New Drug Application is a Major Milestone for Psychedelic-Assisted Therapy

Articles

October 13, 2023

Daubert Challenges Based on an Expert’s Lack of Qualifications

Client Alerts-Psychedelics and Mental Health Therapeutics

September 6, 2023

Psychedelic-Assisted Therapy – First Professional Practice Guidelines

Articles

July 14, 2023

Disclosure of Certain Material Health Care Transactions in NYS

Articles

January 29, 2023

Transitioning for FDA EUA Expiration

Articles

September 22, 2022

APA Issues Position Statement on Psychedelics Use

Articles

September 15, 2022

Kraus, Glasgow, The Limitations of Judicial Discretion

Articles

August 19, 2022

BIPOC Underrepresented in Ketamine Clinical Trials

Articles

August 18, 2022

Markov, Improving Diversity In Psychedelics Research

Articles

August 10, 2022

FDA Issues Draft Guidance on Diversity and Inclusion in Clinical Trials

Articles

May 10, 2022

PREP Act: Limitations of Immunity and Fed Court Jurisdiction

Articles

May 1, 2022

No Surprises Act to Protect Patients from Balance Billing

Articles

March 4, 2022

How the Pandemic Brought Science to the Forefront of Public Consciousness

Articles

February 18, 2022

Cannabis Regulations, Marijuana Regulation and Taxation Act (MRTA)

Articles

January 21, 2022

Hujer, The State of Cannabis in New York

Articles

December 21, 2021

Smith, Kraus, Limit Legal Risks, Medical Device Regulations

Client Alerts-Health Care and Life Sciences

December 1, 2021

Repeal of Final Medicare Coverage Rule

Client Alerts-Cannabis

October 20, 2021

Cannabis Growers Currently Unprotected by New York State’s Seed Law

Client Alerts-Cannabis

September 3, 2021

Key Appointments to Office of Cannabis Mgmt, Cannabis Control Board

Articles

July 22, 2021

Kraus, Regulatory Risk Assessment vs. Tort Law Causation

Client Alerts-Cannabis

July 15, 2021

Cannabis Entrepreneurs Should Plan Banking Strategy Now

Client Alerts-Cannabis

June 30, 2021

Marijuana Regulation and Taxation Act – Part 1: Licensing Guidelines

Articles

June 15, 2021

Hurdles in Baby Food Contamination Class Action

Articles

May 26, 2021

Kraus, Schmidt, PREP Act Immunity, Shareholder Derivative Litigation

Articles

May 25, 2021

Keefer, Federal Health Care Program Exclusion Lists

Articles

May 21, 2021

Mulvehill, Pincelli, Legalized Recreational Marijuana in New York

Client Alerts-Labor and Employment Client Alerts-Cannabis

April 1, 2021

Legalized Recreational Marijuana Use Comes to the NYS Workplace

Client Alerts-Cannabis

April 1, 2021

New York State Legalizes Marijuana for Adult Use

Articles

March 26, 2021

Kraus, Smith, Lessons From the COVID-19 Pandemic

Articles

March 19, 2021

Keefer, HHS, Stark Law and Anti-Kickback Statute

Articles

February 19, 2021

Hujer, Cannabis Update: Hemp Applications Take Shape

Articles

January 15, 2021

Hujer, Planning for NYS 2021 Hemp Regulations

Articles

December 7, 2020

Kraus, COVID-19 Vaccines, Litigation Opportunities Unlikely

Articles

June 17, 2020

Glasgow, MDL Courts, Rule 702 Reform

Articles

May 1, 2020

Keefer, CARES Act Increases Medicare Provider Payments

Client Alerts-Health Care and Life Sciences

April 9, 2020

NYS Executive Orders Facilitate the Provision of Health Care Services

March 25, 2020

COVID-19: HHS Secretary Issues Medicare Telehealth Waivers

Articles

March 13, 2020

NYS Seed Law Protects Hemp Growers

Articles

January 2, 2020

Hujer, Key Lessons For Hemp Companies

Client Alerts-Psychedelics and Mental Health Therapeutics Client Alerts-Health Care and Life Sciences

September 10, 2024

FDA Denies Approval of New Drug Application for MDMA and Requests Additional Study

Articles

August 8, 2024

What’s Next for MDMA?

Client Alerts-Litigation

July 16, 2024

The End of Chevron Deference and a Monumental Shift in the Regulatory Power of Administrative Agencies

Articles

July 12, 2024

The FTC’s Non-Compete Ban: Anticipated Impacts on the Health Care Industry

Articles

July 8, 2024

AI Demystified: The Transformative Impact of AI in Health Care

Client Alerts-Health Care and Life Sciences

June 10, 2024

FDA Will Not Object to Qualified Health Claims for Yogurt for Type 2 Diabetes Risk Reduction

Articles

April 12, 2024

Next-Gen Medical Devices: Evolving with AI to Ensure Safety and Efficacy

Articles

March 25, 2024

Second Circuit Baby Food Ruling Disregards FDA’s Expertise

Client Alerts-Psychedelics and Mental Health Therapeutics

March 21, 2024

FDA Breakthrough Therapy Designation for LSD Formulation

Articles

January 19, 2024

The Direct Primary Care Model: Considerations for NY Providers, Patients and Employers

Client Alerts-Psychedelics and Mental Health Therapeutics

January 3, 2024

Progress for Research Funding on Psychedelics for Military Personnel and Veterans/First Responders

Client Alerts-Psychedelics and Mental Health Therapeutics

December 21, 2023

New Drug Application is a Major Milestone for Psychedelic-Assisted Therapy

Articles

October 13, 2023

Daubert Challenges Based on an Expert’s Lack of Qualifications

Client Alerts-Psychedelics and Mental Health Therapeutics

September 6, 2023

Psychedelic-Assisted Therapy – First Professional Practice Guidelines

Articles

July 14, 2023

Disclosure of Certain Material Health Care Transactions in NYS

Articles

January 29, 2023

Transitioning for FDA EUA Expiration

Articles

September 22, 2022

APA Issues Position Statement on Psychedelics Use

Articles

September 15, 2022

Kraus, Glasgow, The Limitations of Judicial Discretion

Articles

August 19, 2022

BIPOC Underrepresented in Ketamine Clinical Trials

Articles

August 18, 2022

Markov, Improving Diversity In Psychedelics Research

Articles

August 10, 2022

FDA Issues Draft Guidance on Diversity and Inclusion in Clinical Trials

Articles

May 10, 2022

PREP Act: Limitations of Immunity and Fed Court Jurisdiction

Articles

May 1, 2022

No Surprises Act to Protect Patients from Balance Billing

Articles

March 4, 2022

How the Pandemic Brought Science to the Forefront of Public Consciousness

Articles

February 18, 2022

Cannabis Regulations, Marijuana Regulation and Taxation Act (MRTA)

Articles

January 21, 2022

Hujer, The State of Cannabis in New York

Articles

December 21, 2021

Smith, Kraus, Limit Legal Risks, Medical Device Regulations

Client Alerts-Health Care and Life Sciences

December 1, 2021

Repeal of Final Medicare Coverage Rule

Client Alerts-Cannabis

October 20, 2021

Cannabis Growers Currently Unprotected by New York State’s Seed Law

Client Alerts-Cannabis

September 3, 2021

Key Appointments to Office of Cannabis Mgmt, Cannabis Control Board

Articles

July 22, 2021

Kraus, Regulatory Risk Assessment vs. Tort Law Causation

Client Alerts-Cannabis

July 15, 2021

Cannabis Entrepreneurs Should Plan Banking Strategy Now

Client Alerts-Cannabis

June 30, 2021

Marijuana Regulation and Taxation Act – Part 1: Licensing Guidelines

Articles

June 15, 2021

Hurdles in Baby Food Contamination Class Action

Articles

May 26, 2021

Kraus, Schmidt, PREP Act Immunity, Shareholder Derivative Litigation

Articles

May 25, 2021

Keefer, Federal Health Care Program Exclusion Lists

Articles

May 21, 2021

Mulvehill, Pincelli, Legalized Recreational Marijuana in New York

Client Alerts-Labor and Employment Client Alerts-Cannabis

April 1, 2021

Legalized Recreational Marijuana Use Comes to the NYS Workplace

Client Alerts-Cannabis

April 1, 2021

New York State Legalizes Marijuana for Adult Use

Articles

March 26, 2021

Kraus, Smith, Lessons From the COVID-19 Pandemic

Articles

March 19, 2021

Keefer, HHS, Stark Law and Anti-Kickback Statute

Articles

February 19, 2021

Hujer, Cannabis Update: Hemp Applications Take Shape

Articles

January 15, 2021

Hujer, Planning for NYS 2021 Hemp Regulations

Articles

December 7, 2020

Kraus, COVID-19 Vaccines, Litigation Opportunities Unlikely

Articles

June 17, 2020

Glasgow, MDL Courts, Rule 702 Reform

Articles

May 1, 2020

Keefer, CARES Act Increases Medicare Provider Payments

Client Alerts-Health Care and Life Sciences

April 9, 2020

NYS Executive Orders Facilitate the Provision of Health Care Services

March 25, 2020

COVID-19: HHS Secretary Issues Medicare Telehealth Waivers

Articles

March 13, 2020

NYS Seed Law Protects Hemp Growers

Articles

January 2, 2020

Hujer, Key Lessons For Hemp Companies

Articles

January 29, 2024

Major Milestone for Psychedelic-Assisted Therapy

Articles

July 1, 2023

FDA Draft Guidance on Clinical Trials for Psychedelics

Kraus, Glasgow, Duty To Warn and the Learned Intermediary Doctrine

Related Insights

Want to Know More?